Sanofi (NASDAQ:SNY) Stock Has Average Target Price of $49.50 According to Analysts

Sanofi (NASDAQ:SNY) has been given an average recommendation of “Hold” by the sixteen analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, three have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $49.50.

Several equities analysts have issued reports on SNY shares. HSBC restated a “buy” rating on shares of Sanofi in a research note on Thursday, September 10th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 29th. Royal Bank Of Canada began coverage on Sanofi in a research report on Tuesday, September 8th. They issued a “sector perform” rating for the company. Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, August 3rd. Finally, Morgan Stanley set a $49.00 price target on Sanofi in a research report on Wednesday, July 8th.

Sanofi Stock Down 1.7%

Shares of NASDAQ:SNY opened at $40.94 on Tuesday. The company has a market capitalization of $99.26 billion, a PE ratio of 21.43, a P/E/G ratio of 1.28 and a beta of 0.35. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21. Sanofi has a twelve month low of $40.89 and a twelve month high of $52.68. The firm has a 50 day simple moving average of $43.77 and a 200-day simple moving average of $44.28.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The firm had revenue of $13.36 billion for the quarter. During the same period last year, the business earned $3.24 earnings per share. The company’s quarterly revenue was up 16.0% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 5.07 EPS for the current fiscal year.

Institutional Trading of Sanofi

Several institutional investors and hedge funds have recently bought and sold shares of SNY. Physician Wealth Advisors Inc. grew its position in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after purchasing an additional 379 shares during the last quarter. Leonteq Securities AG boosted its stake in shares of Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares during the period. Western Wealth Management LLC acquired a new stake in shares of Sanofi during the first quarter worth about $29,000. Fairway Wealth LLC purchased a new position in shares of Sanofi during the first quarter worth about $32,000. Finally, Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Sanofi by 544.4% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.